Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri"), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor, for the purchase and sale of 2,228,940 Common Shares (or Common Share equivalents in lieu thereof) at a purchase price of $1.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $3.3 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, Pluri will issue and sell unregistered warrants to purchase up to 2,228,940 Common Shares (the "Warrants"). The Warrants will have an exercise price of $1.65 per share, will be initially exercisable six months following the date of issuance, and will expire five and a half years from the date of issuance.